Nano-sized drug delivery systems to potentiate the immune checkpoint blockade therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shim, Man Kyu | - |
dc.contributor.author | Song, Su Kyung | - |
dc.contributor.author | Jeon, Seong Ik | - |
dc.contributor.author | Hwang, Kwang Yeon | - |
dc.contributor.author | Kim, Kwangmeyung | - |
dc.date.accessioned | 2022-08-13T02:40:34Z | - |
dc.date.available | 2022-08-13T02:40:34Z | - |
dc.date.created | 2022-08-12 | - |
dc.date.issued | 2022-06-03 | - |
dc.identifier.issn | 1742-5247 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/142976 | - |
dc.description.abstract | Introduction Immune checkpoint blockade (ICB) therapy is now FDA-approved for the treatment of various tumor types. By removing inhibitory signals for T-cell activation and disrupting the immune escape mechanism of tumor cells, ICB therapy has shown considerable efficacy with complete tumor regression in patients. However, patients respond poorly to this therapy and show limited response rates owing to the immunosuppressive tumor microenvironment (ITM) in cold tumors. Areas covered In this review, recent advances and progress in the use of nano-sized drug delivery system (Nano-DDS) to potentiate the ICB therapy by reversing cold tumors with an ITM into immunogenic hot tumors are discussed. The types of immunogenic cell death (ICD) inducers that initiate or enhance antitumor immune responses are classified, and their extensive combination with immune modulators using Nano-DDS is highlighted. Expert opinion Nano-DDS can be efficiently combined with ICD inducers and immune modulators and trigger a potent antitumor immune response based on a comprehensive approach to the cancer-immunity cycle. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | TAYLOR & FRANCIS LTD | - |
dc.subject | IMMUNOGENIC CELL-DEATH | - |
dc.subject | MESOPOROUS SILICA NANOPARTICLES | - |
dc.subject | POLYSIALIC ACID NANOPARTICLES | - |
dc.subject | CANCER-IMMUNOTHERAPY | - |
dc.subject | RADIOTHERAPY | - |
dc.subject | COMBINATION | - |
dc.subject | ADJUVANTS | - |
dc.subject | PARADIGM | - |
dc.subject | TUMORS | - |
dc.title | Nano-sized drug delivery systems to potentiate the immune checkpoint blockade therapy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Hwang, Kwang Yeon | - |
dc.identifier.doi | 10.1080/17425247.2022.2081683 | - |
dc.identifier.scopusid | 2-s2.0-85131660457 | - |
dc.identifier.wosid | 000802988300001 | - |
dc.identifier.bibliographicCitation | EXPERT OPINION ON DRUG DELIVERY, v.19, no.6, pp.641 - 652 | - |
dc.relation.isPartOf | EXPERT OPINION ON DRUG DELIVERY | - |
dc.citation.title | EXPERT OPINION ON DRUG DELIVERY | - |
dc.citation.volume | 19 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 641 | - |
dc.citation.endPage | 652 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | IMMUNOGENIC CELL-DEATH | - |
dc.subject.keywordPlus | MESOPOROUS SILICA NANOPARTICLES | - |
dc.subject.keywordPlus | POLYSIALIC ACID NANOPARTICLES | - |
dc.subject.keywordPlus | CANCER-IMMUNOTHERAPY | - |
dc.subject.keywordPlus | RADIOTHERAPY | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | ADJUVANTS | - |
dc.subject.keywordPlus | PARADIGM | - |
dc.subject.keywordPlus | TUMORS | - |
dc.subject.keywordAuthor | Nanomedicine | - |
dc.subject.keywordAuthor | drug delivery | - |
dc.subject.keywordAuthor | cancer immunotherapy | - |
dc.subject.keywordAuthor | immune checkpoint blockade | - |
dc.subject.keywordAuthor | combination therapy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.